Present and future perspectives in early diagnosis and monitoring for progressive fibrosing interstitial lung diseases

被引:2
|
作者
Stanel, Stefan Cristian [1 ,2 ]
Rivera-Ortega, Pilar [1 ]
机构
[1] Univ Manchester, Wythenshawe Hosp, NHS Fdn Trust,North West Lung Ctr, Interstitial Lung Dis ILD Unit, Manchester, England
[2] Univ Manchester, Fac Biol, Med & Hlth, Manchester, England
关键词
progressive fibrosing interstitial lung disease; progressive pulmonary fibrosis; interstitial lung disease; idiopathic pulmonary fibrosis; PF-ILD; PPF; CHRONIC HYPERSENSITIVITY PNEUMONITIS; IDIOPATHIC PULMONARY-FIBROSIS; TELOMERE LENGTH; MULTIDISCIPLINARY;
D O I
10.3389/fmed.2023.1114722
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Progressive fibrosing interstitial lung diseases (PF-ILDs) represent a group of conditions of both known and unknown origin which continue to worsen despite standard treatments, leading to respiratory failure and early mortality. Given the potential to slow down progression by initiating antifibrotic therapies where appropriate, there is ample opportunity to implement innovative strategies for early diagnosis and monitoring with the goal of improving clinical outcomes. Early diagnosis can be facilitated by standardizing ILD multidisciplinary team (MDT) discussions, implementing machine learning algorithms for chest computed-tomography quantitative analysis and novel magnetic-resonance imaging techniques, as well as measuring blood biomarker signatures and genetic testing for telomere length and identification of deleterious mutations in telomere-related genes and other single-nucleotide polymorphisms (SNPs) linked to pulmonary fibrosis such as rs35705950 in the MUC5B promoter region. Assessing disease progression in the post COVID-19 era also led to a number of advances in home monitoring using digitally-enabled home spirometers, pulse oximeters and other wearable devices. While validation for many of these innovations is still in progress, significant changes to current clinical practice for PF-ILDs can be expected in the near future.
引用
收藏
页数:7
相关论文
共 50 条
  • [1] Progressive fibrosing interstitial lung diseases: current practice in diagnosis and management
    Wijsenbeek, Marlies
    Kreuter, Michael
    Olson, Amy
    Fischer, Aryeh
    Bendstrup, Elisabeth
    Wells, Christopher D.
    Denton, Christopher P.
    Mounir, Baher
    Zouad-Lejour, Leila
    Quaresma, Manuel
    Cottin, Vincent
    CURRENT MEDICAL RESEARCH AND OPINION, 2019, 35 (11) : 2015 - 2024
  • [2] Nintedanib in Progressive Fibrosing Interstitial Lung Diseases
    Kao, Jui-Hung
    Huang, Hsin-Tuan
    Li, Ko-Jen
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (08): : 780 - 781
  • [3] Nintedanib in Progressive Fibrosing Interstitial Lung Diseases
    Flaherty, K. R.
    Wells, A. U.
    Cottin, V
    Devaraj, A.
    Walsh, S. L. F.
    Inoue, Y.
    Richeldi, L.
    Kolb, M.
    Tetzlaff, K.
    Stowasser, S.
    Coeck, C.
    Clerisme-Beaty, E.
    Rosenstock, B.
    Quaresma, M.
    Haeufel, T.
    Goeldner, R-G
    Schlenker-Herceg, R.
    Brown, K. K.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (18): : 1718 - 1727
  • [4] Nintedanib in progressive fibrosing interstitial lung diseases
    Hadjiski, D.
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 2020, 79 (04): : 393 - 394
  • [5] Treatment of progressive fibrosing interstitial lung diseases: a milestone in the management of interstitial lung diseases
    Cottin, Vincent
    EUROPEAN RESPIRATORY REVIEW, 2019, 28 (153):
  • [6] The natural history of progressive fibrosing interstitial lung diseases
    Kolb, Martin
    Vasakova, Martina
    RESPIRATORY RESEARCH, 2019, 20 (1)
  • [7] Progressive Fibrosing Interstitial Lung Diseases: A Current Perspective
    Albera, Carlo
    Verri, Giulia
    Sciarrone, Federico
    Sitia, Elena
    Mangiapia, Mauro
    Solidoro, Paolo
    BIOMEDICINES, 2021, 9 (09)
  • [8] Nintedanib in Progressive Fibrosing Interstitial Lung Diseases Reply
    Flaherty, Kevin R.
    Wells, Athol U.
    Brown, Kevin K.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (08): : 781 - 781
  • [9] The natural history of progressive fibrosing interstitial lung diseases
    Martin Kolb
    Martina Vašáková
    Respiratory Research, 20
  • [10] The natural history of progressive fibrosing interstitial lung diseases
    Brown, Kevin K.
    Martinez, Fernando J.
    Walsh, Simon L. F.
    Thannickal, Victor J.
    Prasse, Antje
    Schlenker-Herceg, Rozsa
    Goeldner, Rainer-Georg
    Clerisme-Beaty, Emmanuelle
    Tetzlaff, Kay
    Cottin, Vincent
    Wells, Athol U.
    EUROPEAN RESPIRATORY JOURNAL, 2020, 55 (06)